Cargando…
HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings
Head and neck squamous cell carcinoma (HNSCC) is a widespread disease with a low survival rate and a high risk of recurrence. Nowadays, immune checkpoint inhibitor (ICI) treatment is approved for HNSCC as a first-line treatment in recurrent and metastatic disease. ICI treatment yields a clear surviv...
Autores principales: | Boschert, Verena, Teusch, Jonas, Aljasem, Anwar, Schmucker, Philipp, Klenk, Nicola, Straub, Anton, Bittrich, Max, Seher, Axel, Linz, Christian, Müller-Richter, Urs D. A., Hartmann, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699574/ https://www.ncbi.nlm.nih.gov/pubmed/33233528 http://dx.doi.org/10.3390/ijms21228770 |
Ejemplares similares
-
The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma
por: Boschert, Verena, et al.
Publicado: (2020) -
PKM2 Modulation in Head and Neck Squamous Cell Carcinoma
por: Boschert, Verena, et al.
Publicado: (2022) -
Preclinical development of a humanized neutralizing antibody targeting HGF
por: Kim, Hyori, et al.
Publicado: (2017) -
Multi-kinase inhibitors and cisplatin for head and neck cancer treatment in vitro
por: Brands, Roman C., et al.
Publicado: (2019) -
Activated HGF-c-Met Axis in Head and Neck Cancer
por: Arnold, Levi, et al.
Publicado: (2017)